Aktis Oncology
Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3.
Overview
Aktis Oncology, based in Boston and listed as AKTS, is a miniprotein alpha-radiopharmaceutical company whose IPO, closed on 12 January 2026 for about 365 million dollars, was the first biotech IPO of the year and funds actinium-225 programmes against Nectin-4 and B7-H3. Its lead, 225Ac-AKY-1189 against Nectin-4, is in a US phase 1b; 225Ac-AKY-2519 against B7-H3 has an IND planned for the first half of 2026 after diagnostic imaging and dosimetry studies; an in-house cGMP radiopharmaceutical facility is due in the second half of 2026; and large pharma investors back it. Nuclide links it to bladder, small-cell lung and prostate cancer, to targeted alpha therapy and alpha-emitter nanogenerators, and to Nectin-4 and B7-H3 as targets. Whether miniproteins can deliver alpha emitters safely is the open question. The targeted alpha therapy page carries the field.
Similar pages
not linked directly; found by shared links- TechnologyRadio-antibody & radio-ADC
Shares Targeted alpha therapy, Actinium-225 and the tag frontier.
- TechnologyRadioligand plus DNA-repair inhibitor combinations
Shares Targeted alpha therapy, Prostate cancer and the tag frontier.
- TechnologyAuger-electron therapy
Shares Targeted alpha therapy and the tag frontier.
- CompanyAriceum Therapeutics
Shares Small-cell lung cancer, Targeted alpha therapy, Actinium-225.
- PathwayLineage plasticity & neuroendocrine transformation
Shares B7-H3, Small-cell lung cancer, Prostate cancer.
- IdeaAlpha radioligands after ADC failure
Shares B7-H3, Targeted alpha therapy, Actinium-225.
- TechnologyAlpha-emitter daughter redistribution ('free daughter' problem)
Shares Alpha-emitter nanogenerators and daughter trapping, Targeted alpha therapy, Actinium-225.
- CompanyTerraPower Isotopes
Shares Alpha-emitter nanogenerators and daughter trapping, Targeted alpha therapy, Actinium-225.